📰 Topline Data News
Page 2 - Topline Data News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Topline Data. Real-time updates on events, politics, business and more.
August 1, 2023
01.08.2023 - WAKIX (pitolisant) Net Revenue Increased ~25% Year-over-Year to $134.2 Million for Second Quarter 2023 Average Number of Patients on WAKIX Increased by ~350 Sequentially to ~5,450 for Second Quarter 2023 Exited Second Quarter 2023 With ~5,600 ...
July 11, 2023
-- Initiation of Stage 2 Approved by Independent Data Safety Monitoring Board Following Review of Stage 1 Safety and Tolerability Data -- -- The Stage 2 Portion of VAX-24 Infant Study Will Include...
April 26, 2023
– Topline Data from fourth cohort of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint –– Company will focus on development of extracellular vesicles ... | April 26, 2023
April 6, 2023
Washington must not raise its expectations too high with regard torelations with Germany in the post-Schroeder era.
January 6, 2023
—Topline Data from Phase 2 PK/PD Study of Brensocatib in Patients with Cystic Fibrosis Show Clear Dose Response at all Evaluated Doses— —Treatment...
January 6, 2023
Same-store sales at NRS retailers in December 2022 increased 9.8% compared to December 2021 and 6.6% compared to November 2022 NEWARK, N.J., Jan. ...
December 12, 2022
12.12.2022 - DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Daré Portfolio Accomplishments Include: Two Additional Portfolio Programs (DARE-GML and ...
November 5, 2022
Washington must adopt a pragmatic, realistic approach towardworking with Germany. Realpolitik should be the order of the day.As the EU member with the largest economy and largest population,Germany is simply too important to be ignored. It is in the U.S.interest to engage Berlin on an issue-by-issue basis, workingtogether where agreement can be reached.
July 3, 2021
Message : Required fields Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased ChemoCentryx, Inc. (NASDAQ: CCXI) securities between November 26, 2019 and May 3, 2021, inclusive (the “Class Period”). Investors have until July 6, 2021 to apply to the Court to be appointed as lead plaintiff in the law...
June 12, 2021
RADNOR, Pa., June 12, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class...